Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myelodysplastic syndromes.

Daniela Cilloni1, Francesca Messa, Sonia Carturan

  • 1Dept. of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano-Torino, Italy. daniela.cilloni@unito.it

Annals of the New York Academy of Sciences
|January 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Blood advances·2026
Same author

Coincidence or Connection? Revisiting the Relationship Between Mastocytosis and Lymphoma.

Mediterranean journal of hematology and infectious diseases·2026
Same author

Targeting BCL-xL in Myeloid Malignancies: From Inhibitors to PROTAC.

Journal of cellular and molecular medicine·2026
Same author

Clonal Dynamics of FLT3-ITD from Diagnosis to Relapse: Ultra-Sensitive Patient-Specific Monitoring by ddPCR.

International journal of molecular sciences·2026
Same author

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Blood·2026
Same author

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Blood advances·2026
Same journal

Multiomics Profiling During Autoimmune Demyelination Highlights a Complex Regulatory Role for Ataxin-1 in B Cells.

Annals of the New York Academy of Sciences·2026
Same journal

Global Trends in Light Pollution and Their Relationship With Socioeconomic Factors.

Annals of the New York Academy of Sciences·2026
Same journal

Wired for Corruption: Inter-Brain Synchrony Encodes Bribery-Related Value Information and Predicts Bribery Agreement.

Annals of the New York Academy of Sciences·2026
Same journal

LM-YOLO: A Lightweight Multi-Scale Enhanced Model for Forest Smoke Detection Using Unmanned Aerial Vehicles.

Annals of the New York Academy of Sciences·2026
Same journal

Polyrhythm Perception and Production: A Scoping Review.

Annals of the New York Academy of Sciences·2026
Same journal

DARTS-CNN-BiLSTM: Intelligent Fault Diagnosis for Computer Numerical Control Machine Tool Feed System.

Annals of the New York Academy of Sciences·2026
See all related articles

Recent advancements have clarified the complex causes of myelodysplastic syndromes (MDS). Understanding these genetic and biological factors in MDS is crucial for developing effective targeted therapies and improving patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
  • The pathogenesis of MDS is complex and heterogeneous, involving genetic and biological abnormalities.

Purpose of the Study:

  • To summarize recent progress in understanding MDS pathogenesis.
  • To highlight the translation of biological findings into clinical applications and therapies for MDS.

Main Methods:

  • Review of recent studies utilizing advanced technologies.
  • Analysis of clinical trials targeting signal transduction pathways and genetic abnormalities.
  • Identification of myelodysplasia-associated antigens.

Main Results:

Related Experiment Videos

  • Significant progress in understanding the genetic and biological basis of MDS.
  • Development of targeted therapies and clinical trials based on identified pathways.
  • Recognition of shared genetic abnormalities between MDS, AML, and CMPD.

Conclusions:

  • Improved understanding of MDS pathogenesis is paving the way for novel therapies.
  • Targeted inhibition of disrupted pathways and immunotherapeutic approaches show promise for tailored MDS treatment.
  • The complexity of MDS pathogenesis contributes to variable clinical outcomes.